effects FR940405-1-00049 9 510 515 794 823 835 869 1002 1023 1039
data FR940405-1-00049 1 511
on FR940405-1-00049 6 512 747 874 998 1040 1084
the FR940405-1-00049 20 513 518 586 619 639 764 772 776 846 861 868 875 914 919 999 1030 1041 1073 1153 1166
reproductive FR940405-1-00049 3 514 793 1001
due FR940405-1-00049 1 516
to FR940405-1-00049 20 517 524 562 605 615 632 637 660 665 671 737 799 863 939 942 959 963 1058 1145 1174
exposure FR940405-1-00049 8 519 614 631 802 873 958 962 1006
of FR940405-1-00049 16 520 585 641 722 755 775 839 848 870 981 1032 1097 1113 1125 1133 1168
nonsmoking FR940405-1-00049 5 521 559 620 654 756
pregnant FR940405-1-00049 6 522 568 655 683 1050 1157
women FR940405-1-00049 7 523 560 569 656 684 740 757
ets FR940405-1-00049 7 525 661 801 943 960 964 1005
has FR940405-1-00049 2 526 601
been FR940405-1-00049 4 527 603 663 797
presented FR940405-1-00049 1 528
in FR940405-1-00049 16 529 571 580 644 675 734 766 808 913 918 924 1007 1062 1148 1165 1177
many FR940405-1-00049 2 530 558
studies FR940405-1-00049 2 531 1151
[ FR940405-1-00049 16 532 591 622 648 685 758 786 811 824 851 885 927 949 986 1016 1044
exs FR940405-1-00049 8 533 592 623 686 812 886 950 987
. FR940405-1-00049 40 534 553 567 593 598 624 629 650 653 687 696 728 760 763 779 788 791 813 826 829 853 856 867 887 902 930 951 956 988 995 1011 1018 1024 1046 1049 1067 1093 1110 1152 1186
3438 FR940405-1-00049 2 535 928
, FR940405-1-00049 43 536 538 540 542 544 546 548 550 578 582 595 611 626 689 691 693 715 717 720 724 746 749 805 815 818 889 891 893 895 897 899 953 976 990 992 1013 1078 1082 1099 1122 1128 1136 1139
492 FR940405-1-00049 2 537 625
4132 FR940405-1-00049 2 539 688
4174 FR940405-1-00049 2 541 690
4208 FR940405-1-00049 3 543 651 692
4273 FR940405-1-00049 3 545 627 694
4285 FR940405-1-00049 1 547
4287 FR940405-1-00049 2 549 596
4299 FR940405-1-00049 3 551 816 854
] FR940405-1-00049 16 552 597 628 652 695 762 790 817 828 855 901 929 955 994 1020 1048
this FR940405-1-00049 6 554 697 729 857 931 1087
is FR940405-1-00049 9 555 635 731 768 904 916 932 1009 1172
important FR940405-1-00049 1 556
since FR940405-1-00049 1 557
continue FR940405-1-00049 1 561
work FR940405-1-00049 1 563
throughout FR940405-1-00049 2 564 944
their FR940405-1-00049 1 565
pregnancies FR940405-1-00049 1 566
working FR940405-1-00049 1 570
indoor FR940405-1-00049 1 572
environments FR940405-1-00049 1 573
without FR940405-1-00049 1 574
tobacco FR940405-1-00049 3 575 616 633
smoking FR940405-1-00049 5 576 610 701 739 1065
restrictions FR940405-1-00049 1 577
as FR940405-1-00049 3 579 922 965
restaurants FR940405-1-00049 1 581
comprise FR940405-1-00049 1 583
one FR940405-1-00049 2 584 1014
most FR940405-1-00049 1 587
heavily FR940405-1-00049 1 588
etsexposed FR940405-1-00049 2 589 1033
groups FR940405-1-00049 1 590
4151 FR940405-1-00049 1 594
low FR940405-1-00049 5 599 642 703 773 849
birthweight FR940405-1-00049 6 600 643 704 767 777 850
also FR940405-1-00049 2 602 969
shown FR940405-1-00049 1 604
be FR940405-1-00049 3 606 837 940
associated FR940405-1-00049 3 607 844 1003
with FR940405-1-00049 5 608 845 1004 1119 1131
paternal FR940405-1-00049 1 609
implying FR940405-1-00049 1 612
passive FR940405-1-00049 3 613 630 700
smoke FR940405-1-00049 6 617 634 872 1061 1069 1181
by FR940405-1-00049 3 618 681 978
mother FR940405-1-00049 2 621 712
estimated FR940405-1-00049 1 636
double FR940405-1-00049 1 638
risk FR940405-1-00049 2 640 975
a FR940405-1-00049 6 645 840 966 979 1063 1160
fullterm FR940405-1-00049 1 646
baby FR940405-1-00049 3 647 723 862
ex FR940405-1-00049 7 649 759 787 825 852 1017 1045
who FR940405-1-00049 3 657 741 1179
are FR940405-1-00049 1 658
exposed FR940405-1-00049 3 659 941 1057
have FR940405-1-00049 4 662 782 796 878
reported FR940405-1-00049 2 664 832
deliver FR940405-1-00049 2 666 742
neonates FR940405-1-00049 2 667 735
that FR940405-1-00049 7 668 744 795 833 909 936 1175
range FR940405-1-00049 1 669
24 FR940405-1-00049 1 670
120 FR940405-1-00049 1 672
grams FR940405-1-00049 2 673 751
lighter FR940405-1-00049 1 674
weight FR940405-1-00049 1 676
than FR940405-1-00049 2 677 753
those FR940405-1-00049 3 678 754 1146
babies FR940405-1-00049 2 679 743
delivered FR940405-1-00049 1 680
nonexposed FR940405-1-00049 1 682
relationship FR940405-1-00049 1 698
between FR940405-1-00049 1 699
and FR940405-1-00049 8 702 725 819 883 946 961 1104 1141
remains FR940405-1-00049 1 705
statistically FR940405-1-00049 1 706
significant FR940405-1-00049 2 707 770
even FR940405-1-00049 1 708
after FR940405-1-00049 1 709
accounting FR940405-1-00049 1 710
for FR940405-1-00049 2 711 1075
's FR940405-1-00049 2 713 973
age FR940405-1-00049 1 714
parity FR940405-1-00049 1 716
social FR940405-1-00049 1 718
class FR940405-1-00049 1 719
sex FR940405-1-00049 1 721
alcohol FR940405-1-00049 1 726
consumption FR940405-1-00049 1 727
effect FR940405-1-00049 2 730 858
more FR940405-1-00049 1 732
apparent FR940405-1-00049 1 733
born FR940405-1-00049 1 736
actively FR940405-1-00049 2 738 1180
weigh FR940405-1-00049 1 745
average FR940405-1-00049 1 748
200 FR940405-1-00049 1 750
less FR940405-1-00049 1 752
4101 FR940405-1-00049 1 761
reduction FR940405-1-00049 1 765
clinically FR940405-1-00049 1 769
at FR940405-1-00049 2 771 1094
end FR940405-1-00049 1 774
distribution FR940405-1-00049 1 778
these FR940405-1-00049 2 780 834
infants FR940405-1-00049 1 781
higher FR940405-1-00049 1 783
perinatal FR940405-1-00049 1 784
mortality FR940405-1-00049 1 785
4239 FR940405-1-00049 3 789 814 896
other FR940405-1-00049 2 792 821
ascribed FR940405-1-00049 1 798
maternal FR940405-1-00049 1 800
include FR940405-1-00049 1 803
miscarriage FR940405-1-00049 1 804
an FR940405-1-00049 2 806 971
increase FR940405-1-00049 2 807 970
congenital FR940405-1-00049 1 809
abnormalities FR940405-1-00049 2 810 1112
numerous FR940405-1-00049 1 820
physiological FR940405-1-00049 1 822
4297 FR940405-1-00049 3 827 900 954
it FR940405-1-00049 1 830
was FR940405-1-00049 3 831 1070 1088
may FR940405-1-00049 4 836 859 877 968
part FR940405-1-00049 1 838
general FR940405-1-00049 1 841
immunosuppressive FR940405-1-00049 1 842
condition FR940405-1-00049 1 843
occurrence FR940405-1-00049 1 847
predispose FR940405-1-00049 1 860
respiratory FR940405-1-00049 1 864
tract FR940405-1-00049 1 865
infections FR940405-1-00049 1 866
environmental FR940405-1-00049 1 871
fetus FR940405-1-00049 2 876 915
longterm FR940405-1-00049 1 879
sequelae FR940405-1-00049 1 880
into FR940405-1-00049 3 881 947 1072
childhood FR940405-1-00049 2 882 945
adulthood FR940405-1-00049 2 884 948
453 FR940405-1-00049 1 888
4181 FR940405-1-00049 1 890
4213 FR940405-1-00049 1 892
4225 FR940405-1-00049 1 894
451 FR940405-1-00049 1 898
there FR940405-1-00049 1 903
limited FR940405-1-00049 2 905 1010
evidence FR940405-1-00049 1 906
which FR940405-1-00049 2 907 1171
suggests FR940405-1-00049 1 908
growth FR940405-1-00049 1 910
retardation FR940405-1-00049 1 911
observed FR940405-1-00049 1 912
reflected FR940405-1-00049 1 917
growing FR940405-1-00049 1 920
child FR940405-1-00049 3 921 937 967
reductions FR940405-1-00049 1 923
lung FR940405-1-00049 1 925
development FR940405-1-00049 1 926
especially FR940405-1-00049 1 933
relevant FR940405-1-00049 1 934
if FR940405-1-00049 1 935
continues FR940405-1-00049 1 938
4177 FR940405-1-00049 1 952
prenatal FR940405-1-00049 1 957
individual FR940405-1-00049 1 972
cancer FR940405-1-00049 2 974 1188
perhaps FR940405-1-00049 1 977
factor FR940405-1-00049 1 980
two FR940405-1-00049 1 982
( FR940405-1-00049 2 983 1053
2 FR940405-1-00049 1 984
) FR940405-1-00049 2 985 1055
465 FR940405-1-00049 1 989
4164 FR940405-1-00049 1 991
4252 FR940405-1-00049 1 993
experimental FR940405-1-00049 1 996
research FR940405-1-00049 1 997
adverse FR940405-1-00049 1 1000
animals FR940405-1-00049 1 1008
however FR940405-1-00049 1 1012
study FR940405-1-00049 1 1015
46 FR940405-1-00049 2 1019 1047
demonstrated FR940405-1-00049 1 1021
such FR940405-1-00049 1 1022
sciatic FR940405-1-00049 1 1025
nerve FR940405-1-00049 1 1026
tissue FR940405-1-00049 3 1027 1043 1115
taken FR940405-1-00049 2 1028 1103
from FR940405-1-00049 2 1029 1156
offspring FR940405-1-00049 1 1031
female FR940405-1-00049 2 1034 1051
mice FR940405-1-00049 3 1035 1052 1158
revealed FR940405-1-00049 3 1036 1116 1159
definite FR940405-1-00049 1 1037
toxic FR940405-1-00049 1 1038
neonatal FR940405-1-00049 1 1042
c57bl/ksj FR940405-1-00049 1 1054
were FR940405-1-00049 3 1056 1102 1108
lowtar FR940405-1-00049 1 1059
cigarette FR940405-1-00049 2 1060 1068
special FR940405-1-00049 1 1064
chamber FR940405-1-00049 2 1066 1074
blown FR940405-1-00049 1 1071
4 FR940405-1-00049 1 1076
minutes FR940405-1-00049 1 1077
5 FR940405-1-00049 1 1079
times FR940405-1-00049 2 1080 1091
daily FR940405-1-00049 2 1081 1092
except FR940405-1-00049 1 1083
weekends FR940405-1-00049 1 1085
when FR940405-1-00049 1 1086
done FR940405-1-00049 1 1089
3 FR940405-1-00049 1 1090
18 FR940405-1-00049 1 1095
days FR940405-1-00049 1 1096
gestation FR940405-1-00049 1 1098
blood FR940405-1-00049 2 1100 1154
samples FR940405-1-00049 2 1101 1155
carbon FR940405-1-00049 2 1105 1162
monoxide FR940405-1-00049 2 1106 1163
levels FR940405-1-00049 1 1107
measured FR940405-1-00049 1 1109
ultrastructural FR940405-1-00049 1 1111
fetal FR940405-1-00049 1 1114
swollen FR940405-1-00049 1 1117
mitochondria FR940405-1-00049 2 1118 1127
distorted FR940405-1-00049 1 1120
cristae FR940405-1-00049 1 1121
some FR940405-1-00049 1 1123
indication FR940405-1-00049 1 1124
deformed FR940405-1-00049 1 1126
darkened FR940405-1-00049 1 1129
nuclei FR940405-1-00049 1 1130
condensations FR940405-1-00049 1 1132
nuclear FR940405-1-00049 1 1134
material FR940405-1-00049 1 1135
lamellar FR940405-1-00049 1 1137
bodies FR940405-1-00049 2 1138 1143
granules FR940405-1-00049 1 1140
myelin FR940405-1-00049 1 1142
similar FR940405-1-00049 1 1144
found FR940405-1-00049 2 1147 1176
human FR940405-1-00049 1 1149
toxicity FR940405-1-00049 1 1150
mean FR940405-1-00049 1 1161
saturation FR940405-1-00049 1 1164
hemoglobin FR940405-1-00049 1 1167
9 FR940405-1-00049 1 1169
% FR940405-1-00049 1 1170
equivalent FR940405-1-00049 1 1173
humans FR940405-1-00049 1 1178
1020 FR940405-1-00049 1 1182
cigarettes FR940405-1-00049 1 1183
per FR940405-1-00049 1 1184
day FR940405-1-00049 1 1185
6. FR940405-1-00049 1 1187
concern FR940405-1-00050 1 0
over FR940405-1-00050 1 1
the FR940405-1-00050 15 2 14 35 53 72 79 90 136 179 187 256 273 277 291 302
carcinogenic FR940405-1-00050 1 3
effects FR940405-1-00050 1 4
of FR940405-1-00050 16 5 37 52 61 70 74 92 97 99 159 181 217 276 279 330 360
ets FR940405-1-00050 9 6 46 86 195 208 247 298 305 324
was FR940405-1-00050 2 7 122
expressed FR940405-1-00050 1 8
in FR940405-1-00050 13 9 55 78 139 147 189 225 267 287 317 327 349 362
many FR940405-1-00050 1 10
comments FR940405-1-00050 1 11
submitted FR940405-1-00050 1 12
to FR940405-1-00050 7 13 45 85 89 125 131 145
docket FR940405-1-00050 1 15
, FR940405-1-00050 34 16 22 24 26 28 30 32 134 164 167 170 219 235 269 299 319 339 402 409 416 423 430 437 444 471 472 473 474 481 484 485 486 490 497
such FR940405-1-00050 1 17
as FR940405-1-00050 4 18 249 270 272
exs FR940405-1-00050 2 19 336
. FR940405-1-00050 16 20 58 65 95 117 120 150 175 178 210 231 255 316 337 342 368
332 FR940405-1-00050 1 21
335 FR940405-1-00050 1 23
338 FR940405-1-00050 1 25
3207 FR940405-1-00050 1 27
3438 FR940405-1-00050 1 29
3440a FR940405-1-00050 1 31
and FR940405-1-00050 9 33 39 171 201 228 264 286 290 297
3449. FR940405-1-00050 1 34
results FR940405-1-00050 4 36 73 180 326
epidemiological FR940405-1-00050 2 38 75
experimental FR940405-1-00050 1 40
studies FR940405-1-00050 7 41 76 106 184 212 289 321
indicate FR940405-1-00050 2 42 197
that FR940405-1-00050 8 43 82 107 185 198 239 304 323
exposure FR940405-1-00050 7 44 84 130 196 209 248 325
is FR940405-1-00050 6 47 87 101 237 306 355
causally FR940405-1-00050 1 48
associated FR940405-1-00050 1 49
with FR940405-1-00050 3 50 112 128
cancer FR940405-1-00050 5 51 94 114 183 266
lung FR940405-1-00050 7 54 93 113 161 182 265 310
chronicallyexposed FR940405-1-00050 1 56
nonsmokers FR940405-1-00050 3 57 127 334
a FR940405-1-00050 13 59 67 109 308 376 382 401 408 415 422 429 436 443
discussion FR940405-1-00050 1 60
this FR940405-1-00050 2 62 233
evidence FR940405-1-00050 5 63 69 96 275 358
follows FR940405-1-00050 1 64
( FR940405-1-00050 17 66 312 375 381 386 391 400 407 414 421 428 435 442 476 480 488 495
) FR940405-1-00050 17 68 315 377 383 388 393 404 411 418 425 432 439 446 478 482 492 499
association._ FR940405-1-00050 1 71
taken FR940405-1-00050 1 77
aggregate FR940405-1-00050 1 80
suggest FR940405-1-00050 1 81
nonsmoker FR940405-1-00050 1 83
causallyrelated FR940405-1-00050 1 88
development FR940405-1-00050 1 91
specificity FR940405-1-00050 1 98
effect FR940405-1-00050 1 100
provided FR940405-1-00050 2 102 282
by FR940405-1-00050 7 103 194 207 246 252 283 333
active FR940405-1-00050 4 104 151 253 261
smoking FR940405-1-00050 4 105 152 254 263
report FR940405-1-00050 1 108
causal FR940405-1-00050 2 110 258
association FR940405-1-00050 2 111 259
[ FR940405-1-00050 4 115 173 335 366
ex FR940405-1-00050 3 116 174 367
4311 FR940405-1-00050 3 118 176 340
] FR940405-1-00050 4 119 177 341 370
it FR940405-1-00050 2 121 236
therefore FR940405-1-00050 1 123
logical FR940405-1-00050 1 124
examine FR940405-1-00050 1 126
passive FR940405-1-00050 2 129 140
tobacco FR940405-1-00050 5 132 262 280 331 350
smoke FR940405-1-00050 6 133 141 149 281 296 351
since FR940405-1-00050 1 135
chemicals FR940405-1-00050 1 137
found FR940405-1-00050 1 138
are FR940405-1-00050 4 142 205 244 250
qualitatively FR940405-1-00050 1 143
similar FR940405-1-00050 2 144 240
those FR940405-1-00050 1 146
mainstream FR940405-1-00050 2 148 295
induces FR940405-1-00050 1 153
all FR940405-1-00050 1 154
four FR940405-1-00050 1 155
major FR940405-1-00050 1 156
histological FR940405-1-00050 1 157
types FR940405-1-00050 2 158 243
human FR940405-1-00050 2 160 309
cancer_squamouscell FR940405-1-00050 1 162
carcinomas FR940405-1-00050 5 163 166 169 204 230
smallcell FR940405-1-00050 2 165 229
largecell FR940405-1-00050 1 168
adenocarcinomas FR940405-1-00050 3 172 200 218
examined FR940405-1-00050 1 186
variation FR940405-1-00050 1 188
tumor FR940405-1-00050 2 190 241
cell FR940405-1-00050 4 191 203 227 242
type FR940405-1-00050 1 192
induced FR940405-1-00050 3 193 245 251
mostly FR940405-1-00050 1 199
squamous FR940405-1-00050 2 202 226
produced FR940405-1-00050 1 206
some FR940405-1-00050 1 211
have FR940405-1-00050 2 213 222
reported FR940405-1-00050 2 214 223
an FR940405-1-00050 1 215
excess FR940405-1-00050 1 216
while FR940405-1-00050 1 220
others FR940405-1-00050 1 221
excesses FR940405-1-00050 1 224
from FR940405-1-00050 1 232
information FR940405-1-00050 1 234
apparent FR940405-1-00050 1 238
unequivocal FR940405-1-00050 1 257
between FR940405-1-00050 2 260 294
humans FR940405-1-00050 2 268 363
well FR940405-1-00050 1 271
corroborative FR940405-1-00050 1 274
carcinogenicity FR940405-1-00050 2 278 361
animal FR940405-1-00050 1 284
bioassays FR940405-1-00050 1 285
vitro FR940405-1-00050 1 288
chemical FR940405-1-00050 2 292 346
similarity FR940405-1-00050 1 293
clearly FR940405-1-00050 1 300
establish FR940405-1-00050 1 301
plausibility FR940405-1-00050 1 303
also FR940405-1-00050 1 307
carcinogen FR940405-1-00050 1 311
table FR940405-1-00050 2 313 343
ii2 FR940405-1-00050 1 314
addition FR940405-1-00050 1 318
biomarker FR940405-1-00050 1 320
verify FR940405-1-00050 1 322
detectable FR940405-1-00050 1 328
uptake FR940405-1-00050 1 329
constituents FR940405-1-00050 1 332
450 FR940405-1-00050 1 338
ii2._ FR940405-1-00050 1 344
43 FR940405-1-00050 1 345
compounds FR940405-1-00050 1 347
identified FR940405-1-00050 1 348
for FR940405-1-00050 1 352
which FR940405-1-00050 1 353
there FR940405-1-00050 1 354
`` FR940405-1-00050 1 356
sufficient FR940405-1-00050 1 357
'' FR940405-1-00050 1 359
or FR940405-1-00050 1 364
animals FR940405-1-00050 1 365
4160 FR940405-1-00050 1 369
acetaldehyde FR940405-1-00050 1 371
acylonitrile FR940405-1-00050 1 372
arsenic FR940405-1-00050 1 373
benz FR940405-1-00050 1 374
anthracene FR940405-1-00050 2 378 419
benzene FR940405-1-00050 1 379
benzo FR940405-1-00050 3 380 385 390
pyrene FR940405-1-00050 5 384 426 433 440 447
b FR940405-1-00050 1 387
fluoranthene FR940405-1-00050 2 389 394
k FR940405-1-00050 1 392
cadmium FR940405-1-00050 1 395
chromium FR940405-1-00050 1 396
vi FR940405-1-00050 1 397
ddt FR940405-1-00050 1 398
dibenz FR940405-1-00050 3 399 406 413
h FR940405-1-00050 3 403 417 445
acridine FR940405-1-00050 2 405 412
j FR940405-1-00050 1 410
dibenzo FR940405-1-00050 4 420 427 434 441
i FR940405-1-00050 1 424
e FR940405-1-00050 1 431
l FR940405-1-00050 1 438
formaldehyde FR940405-1-00050 1 448
hydrazine FR940405-1-00050 1 449
lead FR940405-1-00050 1 450
nickel FR940405-1-00050 1 451
nnitrosodiethanolamine FR940405-1-00050 1 452
nnitrosodiethylamine FR940405-1-00050 1 453
n FR940405-1-00050 2 454 457
â€™ FR940405-1-00050 2 455 458
-nitrosodimethylamine FR940405-1-00050 1 456
-nitrosonornicotine FR940405-1-00050 1 459
nnitrosopiperidine FR940405-1-00050 1 460
nnitrosodinpropylamine FR940405-1-00050 1 461
nnitrosopyrrolidine FR940405-1-00050 1 462
nnitrosodinbutylamine FR940405-1-00050 1 463
ortho- FR940405-1-00050 1 464
toluidine FR940405-1-00050 1 465
styrene FR940405-1-00050 1 466
urethane FR940405-1-00050 1 467
vinyl FR940405-1-00050 1 468
chloride FR940405-1-00050 1 469
1 FR940405-1-00050 1 470
4- FR940405-1-00050 1 475
methylnitrosamino FR940405-1-00050 1 477
-1- FR940405-1-00050 1 479
- FR940405-1-00050 1 483
7hdibenzo FR940405-1-00050 1 487
c FR940405-1-00050 1 489
g FR940405-1-00050 1 491
carbazole FR940405-1-00050 1 493
indeno FR940405-1-00050 1 494
1,2,3 FR940405-1-00050 1 496
-cd FR940405-1-00050 1 498
pryene FR940405-1-00050 1 500
( FR940405-1-00051 8 0 275 299 394 410 424 517 1173
b FR940405-1-00051 1 1
) FR940405-1-00051 8 2 277 301 406 419 441 525 1175
epidemiological FR940405-1-00051 3 3 13 170
and FR940405-1-00051 28 4 30 94 160 207 216 273 295 343 421 434 522 605 630 676 683 692 701 735 779 784 807 814 1168 1190 1199 1282 1294
experimental FR940405-1-00051 2 5 584
studies FR940405-1-00051 19 6 14 29 164 171 239 256 370 402 454 485 492 501 516 538 586 601 758 774
. FR940405-1-00051 65 7 25 41 82 100 127 137 165 192 240 266 281 333 336 354 383 455 477 493 526 536 546 571 574 596 603 609 626 651 665 699 705 732 756 773 798 803 829 832 876 879 921 924 957 991 994 1034 1037 1040 1058 1061 1081 1084 1103 1106 1128 1132 1135 1153 1216 1238 1246 1271 1274 1301
there FR940405-1-00051 2 8 615
are FR940405-1-00051 6 9 468 486 502 510 616
at FR940405-1-00051 3 10 1116 1176
least FR940405-1-00051 1 11
32 FR940405-1-00051 2 12 677
that FR940405-1-00051 17 15 32 200 243 285 320 357 461 479 507 551 614 711 760 941 952 1220
have FR940405-1-00051 7 16 539 612 708 775 1043 1087
attempted FR940405-1-00051 1 17
to FR940405-1-00051 38 18 146 220 232 235 245 264 328 351 400 416 436 470 483 633 689 719 728 769 789 823 843 893 897 946 962 969 986 1007 1050 1071 1076 1091 1149 1165 1194 1260 1266
evaluate FR940405-1-00051 1 19
the FR940405-1-00051 63 20 130 141 144 149 152 166 201 208 238 241 250 258 292 305 323 358 366 395 425 446 458 495 514 530 541 594 620 634 652 659 666 680 712 720 729 744 750 761 770 782 793 869 872 925 939 943 954 1016 1025 1051 1142 1202 1207 1211 1226 1242 1261 1278 1283 1286 1290 1298
carcinogenic FR940405-1-00051 3 21 557 617
potential FR940405-1-00051 2 22 385
of FR940405-1-00051 46 23 143 151 163 169 196 210 225 237 288 291 314 341 349 379 387 397 429 500 532 543 561 580 599 623 637 641 668 714 763 786 851 871 927 949 984 1015 1120 1145 1158 1183 1206 1249 1285 1289 1297
ets FR940405-1-00051 6 24 174 205 246 265 591
osha FR940405-1-00051 3 26 139 577
analyzed FR940405-1-00051 1 27
these FR940405-1-00051 9 28 255 369 452 508 600 757 958 1221
determined FR940405-1-00051 1 31
14 FR940405-1-00051 3 33 1188 1236
were FR940405-1-00051 17 34 74 96 175 462 673 737 809 836 882 960 1066 1223 1228 1244 1252 1258
positive FR940405-1-00051 3 35 78 404
for FR940405-1-00051 19 36 134 270 308 445 644 695 848 868 900 916 938 967 981 1005 1074 1187 1233 1264
an FR940405-1-00051 3 37 855 1234
association FR940405-1-00051 2 38 145
[ FR940405-1-00051 20 39 80 98 128 279 331 569 607 703 796 827 874 919 989 1035 1056 1079 1101 1133 1269
exs FR940405-1-00051 4 40 81 99 797
436 FR940405-1-00051 1 42
, FR940405-1-00051 59 43 45 47 49 51 53 55 57 59 61 63 65 67 69 72 84 86 88 90 93 102 104 106 108 110 112 114 116 118 120 122 124 180 184 228 389 407 420 457 519 576 686 800 819 822 862 867 889 892 906 911 972 977 980 1000 1063 1161 1164 1178
465 FR940405-1-00051 1 44
4106 FR940405-1-00051 1 46
4119 FR940405-1-00051 1 48
4121 FR940405-1-00051 1 50
4142 FR940405-1-00051 1 52
4143 FR940405-1-00051 1 54
4153 FR940405-1-00051 1 56
4158 FR940405-1-00051 1 58
4187 FR940405-1-00051 1 60
4252 FR940405-1-00051 1 62
4275 FR940405-1-00051 1 64
4276 FR940405-1-00051 1 66
4292 FR940405-1-00051 1 68
4300 FR940405-1-00051 1 70
] FR940405-1-00051 20 71 92 126 138 283 335 573 611 707 802 831 878 923 993 1039 1060 1083 1105 1137 1273
5 FR940405-1-00051 5 73 863 912 973 1001
equivocal FR940405-1-00051 2 75 97
with FR940405-1-00051 5 76 188 403 587 670
a FR940405-1-00051 21 77 223 267 289 339 347 488 533 582 597 662 844 860 894 963 975 982 998 1003 1028 1117
trend FR940405-1-00051 1 79
44 FR940405-1-00051 1 83
447 FR940405-1-00051 1 85
4117 FR940405-1-00051 1 87
4122 FR940405-1-00051 1 89
4171 FR940405-1-00051 1 91
13 FR940405-1-00051 2 95 1267
435 FR940405-1-00051 1 101
438 FR940405-1-00051 1 103
452 FR940405-1-00051 1 105
4118 FR940405-1-00051 1 107
4148 FR940405-1-00051 1 109
4164 FR940405-1-00051 1 111
4175 FR940405-1-00051 1 113
4183 FR940405-1-00051 1 115
4192 FR940405-1-00051 1 117
4283 FR940405-1-00051 1 119
4286 FR940405-1-00051 1 121
4296 FR940405-1-00051 1 123
4326 FR940405-1-00051 1 125
see FR940405-1-00051 1 129
risk FR940405-1-00051 3 131 251 360
assessment FR940405-1-00051 1 132
section FR940405-1-00051 1 133
further FR940405-1-00051 2 135 1231
discussion FR940405-1-00051 2 136 598
considered FR940405-1-00051 1 140
consistency FR940405-1-00051 1 142
determine FR940405-1-00051 1 147
if FR940405-1-00051 2 148 1225
finding FR940405-1-00051 1 150
same FR940405-1-00051 2 153 1262
exposure FR940405-1-00051 9 154 206 244 263 327 350 435 858 1232
effect FR940405-1-00051 1 155
occurred FR940405-1-00051 1 156
in FR940405-1-00051 30 157 185 316 322 368 448 451 490 513 593 619 679 739 753 781 811 838 885 930 1011 1024 1027 1046 1068 1125 1141 1201 1210 1241 1275
different FR940405-1-00051 4 158 161 178 182
populations FR940405-1-00051 2 159 183
types FR940405-1-00051 2 162 499
great FR940405-1-00051 1 167
number FR940405-1-00051 1 168
available FR940405-1-00051 1 172
on FR940405-1-00051 3 173 181 427
conducted FR940405-1-00051 2 176 303
by FR940405-1-00051 7 177 304 657 743 749 792 1030
researchers FR940405-1-00051 1 179
various FR940405-1-00051 2 186 453
countries FR940405-1-00051 1 187
diverse FR940405-1-00051 1 189
study FR940405-1-00051 7 190 466 475 755 1029 1127 1277
designs FR940405-1-00051 1 191
this FR940405-1-00051 6 193 355 527 754 1126 1276
extensive FR940405-1-00051 1 194
amount FR940405-1-00051 1 195
data FR940405-1-00051 4 197 467 476 549
increases FR940405-1-00051 1 198
confidence FR940405-1-00051 2 199 531
associations FR940405-1-00051 1 202
seen FR940405-1-00051 3 203 450 1067
between FR940405-1-00051 1 204
development FR940405-1-00051 1 209
lung FR940405-1-00051 5 211 671 805 1041 1243
cancer FR940405-1-00051 2 212 359
is FR940405-1-00051 8 213 217 247 338 344 505 578 766
externally FR940405-1-00051 1 214
consistent FR940405-1-00051 1 215
not FR940405-1-00051 6 218 443 487 511 748 767
due FR940405-1-00051 1 219
artifacts FR940405-1-00051 1 221
or FR940405-1-00051 5 222 412 590 1021 1180
product FR940405-1-00051 1 224
some FR940405-1-00051 2 226 262
unidentified FR940405-1-00051 1 227
indirect FR940405-1-00051 1 229
factors FR940405-1-00051 1 230
unlikely FR940405-1-00051 1 231
be FR940405-1-00051 4 233 363 417 481
common FR940405-1-00051 2 234 248
all FR940405-1-00051 1 236
fact FR940405-1-00051 1 242
dilutes FR940405-1-00051 1 249
estimates FR940405-1-00051 1 252
derived FR940405-1-00051 1 253
from FR940405-1-00051 7 254 464 473 497 935 1053 1111
because FR940405-1-00051 1 257
comparison FR940405-1-00051 1 259
group FR940405-1-00051 2 260 1214
has FR940405-1-00051 2 261 371
recent FR940405-1-00051 1 268
centers FR940405-1-00051 1 269
disease FR940405-1-00051 1 271
control FR940405-1-00051 1 272
prevention FR940405-1-00051 1 274
cdc FR940405-1-00051 1 276
report FR940405-1-00051 1 278
ex FR940405-1-00051 15 280 332 570 608 704 828 875 920 990 1036 1057 1080 1102 1134 1270
450 FR940405-1-00051 2 282 334
found FR940405-1-00051 3 284 1191 1219
100 FR940405-1-00051 3 286 812 1008
% FR940405-1-00051 8 287 675 678 691 694 937 948 1014
subset FR940405-1-00051 1 290
national FR940405-1-00051 2 293 306
health FR940405-1-00051 2 294 309
nutrition FR940405-1-00051 1 296
evaluation FR940405-1-00051 1 297
survey FR940405-1-00051 1 298
nhanes FR940405-1-00051 1 300
iii FR940405-1-00051 1 302
center FR940405-1-00051 1 307
statistics FR940405-1-00051 1 310
had FR940405-1-00051 2 311 325
detectable FR940405-1-00051 2 312 326
levels FR940405-1-00051 1 313
cotinine FR940405-1-00051 2 315 337
their FR940405-1-00051 2 317 696
bodies FR940405-1-00051 1 318
indicating FR940405-1-00051 1 319
everyone FR940405-1-00051 1 321
sample FR940405-1-00051 1 324
tobacco FR940405-1-00051 6 329 352 439 624 764 1151
smoke FR940405-1-00051 23 330 353 440 545 553 563 568 589 625 640 660 731 752 765 791 826 896 1052 1073 1108 1113 1152 1171
metabolite FR940405-1-00051 1 340
nicotine FR940405-1-00051 1 342
used FR940405-1-00051 1 345
as FR940405-1-00051 3 346 391 687
surrogate FR940405-1-00051 1 348
indicates FR940405-1-00051 1 356
may FR940405-1-00051 3 361 480 554
indeed FR940405-1-00051 1 362
greater FR940405-1-00051 2 364 724
since FR940405-1-00051 2 365 494
relationship FR940405-1-00051 1 367
been FR940405-1-00051 3 372 1044 1089
more FR940405-1-00051 2 373 556
exposed FR940405-1-00051 17 374 377 380 628 718 727 788 818 842 888 961 1017 1049 1070 1148 1155 1259
versus FR940405-1-00051 2 375 381
less FR940405-1-00051 1 376
instead FR940405-1-00051 1 378
nonexposed FR940405-1-00051 1 382
many FR940405-1-00051 1 384
sources FR940405-1-00051 1 386
bias FR940405-1-00051 6 388 393 409 423 521 524
such FR940405-1-00051 1 390
publication FR940405-1-00051 1 392
tendency FR940405-1-00051 1 396
scientific FR940405-1-00051 1 398
journals FR940405-1-00051 1 399
publish FR940405-1-00051 1 401
results FR940405-1-00051 3 405 496 1248
misclassification FR940405-1-00051 2 408 520
smokers FR940405-1-00051 2 411 414
former FR940405-1-00051 1 413
claiming FR940405-1-00051 1 415
nonsmokers FR940405-1-00051 1 418
recall FR940405-1-00051 2 422 523
reliance FR940405-1-00051 1 426
selfreporting FR940405-1-00051 1 428
both FR940405-1-00051 3 430 498 1159
personal FR940405-1-00051 1 431
smoking FR940405-1-00051 1 432
habits FR940405-1-00051 1 433
others FR940405-1-00051 1 437
' FR940405-1-00051 1 438
can FR940405-1-00051 1 442
account FR940405-1-00051 1 444
elevation FR940405-1-00051 1 447
risks FR940405-1-00051 2 449 460
also FR940405-1-00051 7 456 709 776 883 1088 1218 1253
relative FR940405-1-00051 1 459
estimated FR940405-1-00051 2 463 472
prospective FR940405-1-00051 2 465 491
similar FR940405-1-00051 3 469 503 1247
those FR940405-1-00051 2 471 950
case/control FR940405-1-00051 1 474
biases FR940405-1-00051 2 478 509
problematic FR940405-1-00051 1 482
casecontrol FR940405-1-00051 2 484 515
problem FR940405-1-00051 1 489
it FR940405-1-00051 1 504
apparent FR940405-1-00051 1 506
important FR940405-1-00051 1 512
eg FR940405-1-00051 1 518
information FR940405-1-00051 1 528
strengthens FR940405-1-00051 1 529
causal FR940405-1-00051 1 534
connection FR940405-1-00051 1 535
animal FR940405-1-00051 2 537 1124
shown FR940405-1-00051 4 540 613 710 1090
carcinogenicity FR940405-1-00051 3 542 762 1093
cigarette FR940405-1-00051 7 544 562 638 790 1072 1107 1122
limited FR940405-1-00051 2 547 768
existing FR940405-1-00051 1 548
suggest FR940405-1-00051 1 550
sidestream FR940405-1-00051 5 552 588 1085 1112 1170
contain FR940405-1-00051 1 555
activity FR940405-1-00051 1 558
per FR940405-1-00051 6 559 865 909 914 1123 1185
milligram FR940405-1-00051 1 560
concentrate FR940405-1-00051 1 564
than FR940405-1-00051 2 565 725
does FR940405-1-00051 1 566
mainstream FR940405-1-00051 3 567 639 825
3689d FR940405-1-00051 1 572
currently FR940405-1-00051 1 575
aware FR940405-1-00051 1 579
only FR940405-1-00051 6 581 821 891 979 1163 1215
few FR940405-1-00051 1 583
inhalation FR940405-1-00051 2 585 794
reported FR940405-1-00051 6 592 777 1045 1138 1245 1280
literature FR940405-1-00051 1 595
follows FR940405-1-00051 1 602
otto FR940405-1-00051 1 604
elmenhorst FR940405-1-00051 1 606
4247 FR940405-1-00051 1 610
constituents FR940405-1-00051 1 618
vapor FR940405-1-00051 1 621
phase FR940405-1-00051 5 622 636 722 746 772
they FR940405-1-00051 3 627 1154 1217
c57b1 FR940405-1-00051 3 629 682 816
blh FR940405-1-00051 2 631 684
mice FR940405-1-00051 7 632 669 685 717 742 787 817
gas FR940405-1-00051 3 635 721 745
12 FR940405-1-00051 1 642
cigarettes FR940405-1-00051 2 643 1055
90 FR940405-1-00051 2 645 1013
minutes FR940405-1-00051 2 646 971
daily FR940405-1-00051 1 647
over FR940405-1-00051 1 648
27 FR940405-1-00051 1 649
months FR940405-1-00051 1 650
particulate FR940405-1-00051 2 653 771
matter FR940405-1-00051 1 654
was FR940405-1-00051 3 655 723 1114
removed FR940405-1-00051 1 656
passing FR940405-1-00051 1 658
through FR940405-1-00051 1 661
cambridge FR940405-1-00051 1 663
filter FR940405-1-00051 1 664
percentages FR940405-1-00051 1 667
adenomas FR940405-1-00051 2 672 734
5.5 FR940405-1-00051 1 674
smokeexposed FR940405-1-00051 1 681
compared FR940405-1-00051 1 688
3.4 FR940405-1-00051 1 690
22 FR940405-1-00051 1 693
respective FR940405-1-00051 1 697
controls FR940405-1-00051 1 698
leuchtenberger FR940405-1-00051 2 700 702
4197 FR940405-1-00051 1 706
rate FR940405-1-00051 1 713
tumors FR940405-1-00051 5 715 806 881 1042 1065
among FR940405-1-00051 1 716
animals FR940405-1-00051 6 726 873 940 951 959 1227
whole FR940405-1-00051 2 730 751
pulmonary FR940405-1-00051 2 733 833
adenocarcinomas FR940405-1-00051 1 736
induced FR940405-1-00051 1 738
snell FR940405-1-00051 1 740
's FR940405-1-00051 1 741
but FR940405-1-00051 1 747
demonstrate FR940405-1-00051 1 759
hyperplasia FR940405-1-00051 4 778 1140 1198 1251
metaplasia FR940405-1-00051 1 780
trachea FR940405-1-00051 1 783
bronchi FR940405-1-00051 1 785
route FR940405-1-00051 1 795
4226 FR940405-1-00051 1 799
4327 FR940405-1-00051 1 801
four FR940405-1-00051 1 804
emphysema FR940405-1-00051 1 808
detected FR940405-1-00051 2 810 837
male FR940405-1-00051 2 813 1256
female FR940405-1-00051 3 815 839 1097
nose FR940405-1-00051 4 820 890 978 1162
fresh FR940405-1-00051 1 824
4135 FR940405-1-00051 1 830
squamous FR940405-1-00051 1 834
neoplasms FR940405-1-00051 1 835
wistar FR940405-1-00051 1 840
rats FR940405-1-00051 5 841 887 1147 1157 1257
1:5 FR940405-1-00051 1 845
smoketoair FR940405-1-00051 2 846 965
mixture FR940405-1-00051 3 847 899 966
15 FR940405-1-00051 1 849
seconds FR940405-1-00051 2 850 903
every FR940405-1-00051 2 852 904
minute FR940405-1-00051 3 853 857 905
during FR940405-1-00051 1 854
11 FR940405-1-00051 1 856
twice FR940405-1-00051 2 859 997
day FR940405-1-00051 3 861 910 999
days FR940405-1-00051 6 864 913 974 1002 1189 1237
week FR940405-1-00051 4 866 915 976 1004
lifespan FR940405-1-00051 1 870
479 FR940405-1-00051 1 877
respiratory FR940405-1-00051 2 880 1287
observed FR940405-1-00051 1 884
fischer344 FR940405-1-00051 1 886
1:10 FR940405-1-00051 1 895
air FR940405-1-00051 1 898
approximately FR940405-1-00051 1 901
30 FR940405-1-00051 2 902 970
7 FR940405-1-00051 1 907
hours FR940405-1-00051 1 908
128 FR940405-1-00051 1 917
weeks FR940405-1-00051 4 918 988 1009 1268
477 FR940405-1-00051 1 922
incidence FR940405-1-00051 1 926
laryngeal FR940405-1-00051 1 928
leukoplakias FR940405-1-00051 1 929
syrian FR940405-1-00051 1 931
golden FR940405-1-00051 1 932
hamsters FR940405-1-00051 3 933 996 1018
ranged FR940405-1-00051 1 934
11.3 FR940405-1-00051 1 936
received FR940405-1-00051 2 942 953
low FR940405-1-00051 1 944
dose FR940405-1-00051 3 945 956 1118
30.6 FR940405-1-00051 1 947
highest FR940405-1-00051 1 955
1:7 FR940405-1-00051 1 964
10 FR940405-1-00051 3 968 1181 1212
period FR940405-1-00051 1 983
up FR940405-1-00051 4 985 1006 1075 1265
52 FR940405-1-00051 1 987
488 FR940405-1-00051 1 992
exposing FR940405-1-00051 1 995
resulted FR940405-1-00051 1 1010
almost FR940405-1-00051 1 1012
having FR940405-1-00051 1 1019
hyperplastic FR940405-1-00051 1 1020
neoplastic FR940405-1-00051 1 1022
changes FR940405-1-00051 2 1023 1222
larynx FR940405-1-00051 1 1026
bernfeld FR940405-1-00051 1 1031
et FR940405-1-00051 2 1032 1130
al FR940405-1-00051 2 1033 1131
430 FR940405-1-00051 1 1038
beagle FR940405-1-00051 1 1047
dogs FR940405-1-00051 1 1048
nonfilter FR940405-1-00051 1 1054
419 FR940405-1-00051 1 1059
however FR940405-1-00051 1 1062
no FR940405-1-00051 2 1064 1239
rabbits FR940405-1-00051 1 1069
51/2 FR940405-1-00051 1 1077
years FR940405-1-00051 1 1078
4149 FR940405-1-00051 1 1082
condensates FR940405-1-00051 1 1086
cause FR940405-1-00051 1 1092
when FR940405-1-00051 2 1094 1255
implanted FR940405-1-00051 2 1095 1115
into FR940405-1-00051 1 1096
osbornemendel FR940405-1-00051 1 1098
rat FR940405-1-00051 1 1099
lungs FR940405-1-00051 1 1100
4127 FR940405-1-00051 1 1104
condensate FR940405-1-00051 1 1109
fraction FR940405-1-00051 1 1110
level FR940405-1-00051 1 1119
one FR940405-1-00051 1 1121
coggins FR940405-1-00051 1 1129
459 FR940405-1-00051 1 1136
epithelial FR940405-1-00051 2 1139 1197
nasal FR940405-1-00051 3 1143 1208 1292
cavity FR940405-1-00051 2 1144 1209
highdosed FR940405-1-00051 1 1146
environmental FR940405-1-00051 1 1150
spraguedawley FR940405-1-00051 1 1156
sexes FR940405-1-00051 1 1160
`` FR940405-1-00051 2 1166 1192
aged FR940405-1-00051 1 1167
diluted FR940405-1-00051 1 1169
'' FR940405-1-00051 2 1172 1196
adss FR940405-1-00051 1 1174
0.1 FR940405-1-00051 1 1177
1 FR940405-1-00051 1 1179
mg FR940405-1-00051 2 1182 1213
particulates FR940405-1-00051 1 1184
meter FR940405-1-00051 1 1186
slight FR940405-1-00051 1 1193
mild FR940405-1-00051 2 1195 1250
inflammation FR940405-1-00051 1 1200
most FR940405-1-00051 1 1203
rostral FR940405-1-00051 1 1204
part FR940405-1-00051 1 1205
reversible FR940405-1-00051 1 1224
kept FR940405-1-00051 1 1229
without FR940405-1-00051 1 1230
additional FR940405-1-00051 1 1235
effects FR940405-1-00051 1 1240
obtained FR940405-1-00051 1 1254
concentrations FR940405-1-00051 1 1263
460 FR940405-1-00051 1 1272
authors FR940405-1-00051 1 1279
hypercellularity FR940405-1-00051 1 1281
thickening FR940405-1-00051 1 1284
epithelium FR940405-1-00051 1 1288
dorsal FR940405-1-00051 1 1291
conchae FR940405-1-00051 1 1293
adjacent FR940405-1-00051 1 1295
wall FR940405-1-00051 1 1296
middle FR940405-1-00051 1 1299
meatus FR940405-1-00051 1 1300
rats FR940405-1-00052 1 0
are FR940405-1-00052 2 1 35
obligatory FR940405-1-00052 1 2
nosebreathers FR940405-1-00052 1 3
, FR940405-1-00052 3 4 30 57
and FR940405-1-00052 7 5 8 14 23 33 41 61
the FR940405-1-00052 6 6 11 15 18 45 51
anatomy FR940405-1-00052 1 7
physiology FR940405-1-00052 1 9
of FR940405-1-00052 3 10 17 27
respiratory FR940405-1-00052 2 12 52
tract FR940405-1-00052 1 13
biochemistry FR940405-1-00052 1 16
lung FR940405-1-00052 1 19
differ FR940405-1-00052 1 20
between FR940405-1-00052 1 21
rodents FR940405-1-00052 2 22 58
humans FR940405-1-00052 2 24 34
. FR940405-1-00052 2 25 54
because FR940405-1-00052 1 26
these FR940405-1-00052 1 28
distinctions FR940405-1-00052 1 29
laboratory FR940405-1-00052 1 31
animals FR940405-1-00052 1 32
likely FR940405-1-00052 1 36
to FR940405-1-00052 1 37
have FR940405-1-00052 2 38 59
different FR940405-1-00052 1 39
deposition FR940405-1-00052 1 40
exposure FR940405-1-00052 1 42
patterns FR940405-1-00052 1 43
for FR940405-1-00052 2 44 55
various FR940405-1-00052 1 46
cigarette FR940405-1-00052 1 47
smoke FR940405-1-00052 1 48
components FR940405-1-00052 1 49
in FR940405-1-00052 1 50
system FR940405-1-00052 1 53
example FR940405-1-00052 1 56
extensive FR940405-1-00052 1 60
complex FR940405-1-00052 1 62
nasal FR940405-1-00052 1 63
turbinates FR940405-1-00052 1 64
where FR940405-1-00052 1 65
significant FR940405-1-00052 1 66
